Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2 Diabetes in The Netherlands

por Gout-Zwart, Judith J., de Jong, Lisa A., Saptenno, Lisanne, Postma, Maarten J.
Publicado 2019

Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation

por Jacobs, Maartje S., de Jong, Lisa A., Postma, Maarten J., Tieleman, Robert G., van Hulst, Marinus
Publicado 2017

Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism

por de Jong, Lisa A, van der Velden, Annette W G, van Hulst, Marinus, Postma, Maarten J
Publicado 2020

The Use of eHealth for Pharmacotherapy Management With Patients With Respiratory Disease, Cardiovascular Disease, or Diabetes: Scoping Review

por Bakema, Robbert, Smirnova, Daria, Biri, Despina, Kocks, Janwillem W H, Postma, Maarten J, de Jong, Lisa A
Publicado 2023

Extended Treatment with Apixaban for Venous Thromboembolism Prevention in the Netherlands: Clinical and Economic Effects

por de Jong, Lisa A., Gout-Zwart, Judith J., Stevanovic, Jelena, Rila, Harrie, Koops, Mike, Huisman, Menno V., Postma, Maarten J.
Publicado 2018

Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings

por de Jong, Lisa A., Groeneveld, Jessie, Stevanovic, Jelena, Rila, Harrie, Tieleman, Robert G., Huisman, Menno V., Postma, Maarten J., van Hulst, Marinus
Publicado 2019

Correction: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings

por de Jong, Lisa A., Groeneveld, Jessie, Stevanovic, Jelena, Rila, Harrie, Tieleman, Robert G., Huisman, Menno V., Postma, Maarten J., van Hulst, Marinus
Publicado 2022